Chimerix Inc. (NASDAQ:CMRX)’s share price traded up 3% during trading on Wednesday . The company traded as high as $4.22 and last traded at $4.14, with a volume of 194,169 shares traded. The stock had previously closed at $4.02.

A number of equities research analysts have recently issued reports on CMRX shares. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $16.98.

The company has a 50-day moving average price of $3.94 and a 200-day moving average price of $5.37. The stock’s market cap is $185.55 million.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.09. The business earned $1.20 million during the quarter, compared to the consensus estimate of $2.79 million. On average, analysts expect that Chimerix Inc. will post ($2.06) earnings per share for the current year.

In other Chimerix news, Director Ernest Mario acquired 10,000 shares of the company’s stock in a transaction dated Friday, May 13th. The shares were acquired at an average cost of $4.53 per share, for a total transaction of $45,300.00. Following the completion of the purchase, the director now owns 331,440 shares of the company’s stock, valued at approximately $1,501,423.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO M Michelle Berrey acquired 13,188 shares of the company’s stock in a transaction dated Friday, June 24th. The stock was acquired at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the completion of the purchase, the chief executive officer now directly owns 258,821 shares of the company’s stock, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

A number of institutional investors have recently modified their holdings of the stock. Morgan Stanley raised its position in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock valued at $1,674,000 after buying an additional 92,005 shares in the last quarter. Trexquant Investment LP raised its position in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 107,484 shares in the last quarter. Finally, Jennison Associates LLC raised its position in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock valued at $11,400,000 after buying an additional 515,029 shares in the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.